Certain painkillers 'could increase risk of heart failure'

Arthritis patients who take common painkillers such as ibuprofen could be at a greater risk of heart failure, according to a new large-scale study.The research, led by the University of Milano-Bicocca in Italy and utilising data from more than eight million patients, has offered evidence that non-steroidal anti-inflammatory drugs (NSAIDs) may lead to an elevated risk of a person being hospitalised with heart problems, meaning caution may need to be employed when using them.The heart health risks of NSAIDsPublished in the British Medical Journal, the study aimed to investigate the cardiovascular safety of NSAIDs and to estimate the risk of hospital admission for heart failure with use of individual NSAIDs.Assessing population-based healthcare databases from the Netherlands, Italy, Germany and the UK, a total of 92,163 hospital admissions for heart failure were identified and matched with 8.2 million healthy controls.It was shown that use of any NSAID within the preceding 14 days was associated with a 19 per cent increase of risk of hospital admission for heart failure, when compared with those who had not used NSAIDs for more than 183 days.This risk was specifically associated with ibuprofen, diclofenac, indomethacin, ketorolac, naproxen, nimesulide, piroxicam, etoricoxib and rofecoxib, with the chances of heart failure doubling among those taking diclofenac, etoricoxib, indomethacin, piroxicam and rofecoxib at very high doses. Even medium doses of indomethacin and etoric...
Source: Arthritis Research UK - Category: Rheumatology Source Type: news

Related Links:

Perhaps you’ve grown as weary as I have of repeated arthritis ads. They appear in frequent rotation on television, online, and in magazines, promoting Enbrel, Humira, Otezla, Xeljanz, and others. If you’ve actually read or listened to these ads, you might have felt perplexed at certain points. Here’s a quick rundown on what they’re saying — and not saying — in one of those ads. “The clock is ticking” Part 1: A teakettle whistles on the stove and a disembodied voice speaks as this ad for Humira opens. “This is your wakeup call. If you have moderate to severe rheumatoid a...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Arthritis Bones and joints Health Inflammation Source Type: blogs
Perhaps you’ve grown as weary as I have of repeated arthritis ads. They appear in frequent rotation on television, online, and in magazines, promoting Enbrel, Humira, Otezla, Xeljanz, and others. If you’ve actually read or listened to these ads, you might have felt perplexed at certain points. Here’s a quick rundown on what they’re saying — and not saying — in one of those ads. “The clock is ticking” Part 1: A teakettle whistles on the stove and a disembodied voice speaks as this ad for Humira opens. “This is your wakeup call. If you have moderate to severe rheumatoid a...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Arthritis Bones and joints Health Inflammation Source Type: blogs
HORSHAM, PA, April 24, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate. If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion ava...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
This study highlighted sex differences in areas that could account for the underuse of the procedure in both sexes, with women affected to a greater extent. Understanding these factors will help address the unmet needs of both sexes after TJA by encouraging future studies and provider education to ensure that all patients are able to access the necessary procedures for pain relief and functional improvement. PMID: 32015251 [PubMed - as supplied by publisher]
Source: The Journal of the American Academy of Orthopaedic Surgeons - Category: Orthopaedics Tags: J Am Acad Orthop Surg Source Type: research
MD+DI has taken a hard look at the private medtech sector and developed this list of 20 private companies we will be paying particularly close attention to in the new year. It was not an easy task. There are so many interesting private companies in the industry right now that we started with a much longer list and whittled it down to the 20 companies that stood out most to us. So without further ado, here are the 20 companies that made the cut: 4C Medical is developing the AltaValve, a transcatheter mitral valve replacement (TMVR) platform designed to address mitr...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
MD+DI has taken a hard look at the private medtech sector and developed this list of 20 private companies we will be paying particularly close attention to in the new year. It was not an easy task. There are so many interesting private companies in the industry right now that we started with a much longer list and whittled it down to the 20 companies that stood out most to us. So without further ado, here are the 20 companies that made the cut: 4C Medical is developing the AltaValve, a transcatheter mitral valve replacement (TMVR) platform designed to address mitr...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
The objective of this study was to determine the burden of 10 health conditions across race and ethnicity for a nationally-representative sample of aging Americans. Data from the 1998 to 2014 waves of the Health and Retirement Study, an ongoing longitudinal-panel study, were analyzed. Those aged over 50 years who identified as Black, Hispanic, or White were included. There were 5510 Blacks, 3423 Hispanics, and 21,168 Whites in the study. At each wave, participants reported if they had cancer, chronic obstructive pulmonary disease, congestive heart failure, diabetes, back pain, hypertension, a fractured hip, myocardial i...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Abstract In the geriatric age group, few studies demonstrate the efficacy of aggressive treatment. Often, a more palliative approach is wanted; such an approach can lead to better quality of life and even a longer life. The author discusses the limits of medical interventions in the elderly, the paucity of data, and the benefits of palliation in certain medical conditions, including dementia, Parkinson, depression, arthritis, congestive heart failure, and pneumonia. The role of frailty is addressed; specific goals of palliative care are delineated, such as reduction of polypharmacy, fall prevention, pain reduction...
Source: Pain Physician - Category: Anesthesiology Authors: Tags: Prim Care Source Type: research
In conclusion, with study of the frailty syndrome still in its infancy, frailty analysis remains a major challenge. It is a challenge that needs to be overcome in order to shed light on the multiple mechanisms involved in the pathogenesis of this syndrome. Although several mechanisms contribute to frailty, immune system alteration seems to play a central role: this syndrome is characterized by increased levels of pro-inflammatory markers and the resulting pro-inflammatory status can have negative effects on various organs. Future studies should aim to better clarify the immune system alteration in frailty, and seek to esta...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
ABSTRACT Objective: To highlight the importance of the new classification criteria for the macrophage activation syndrome (MAS) in systemic juvenile idiopathic arthritis in order to reduce morbidity and mortality outcome related to this disease. Case description: A 12-year-old female patient with diagnosis of systemic juvenile idiopathic arthritis under immunosuppression therapy for two years developed cough, acute precordial chest pain, tachypnea, tachycardia and hypoxemia for two days. Chest tomography showed bilateral laminar pleural effusion with bibasilar consolidation. The electrocardiogram was consistent with acute ...
Source: Revista Paulista de Pediatria - Category: Pediatrics Source Type: research
More News: Aleve | Arthritis | Cardiology | Cardiovascular | Databases & Libraries | Diclofenac | Health | Heart | Heart Failure | Hospital Management | Hospitals | Ibuprofen | Indomethacin | Naproxen | Pain | Piroxicam | Rheumatology | Study | Vioxx | Voltaren